Sex- and KRAS mutation-associated ferroptosis and redox signatures in colorectal cancer: an integrative multi-cohort analysis

KRAS mutations are associated with poorer prognosis in males with colorectal cancer (CRC) compared with females and KRAS wild-type (WT) tumors, yet the sex-specific mechanisms remain unclear. Emerging studies suggest that ferroptosis is suppressed in KRAS-mutant CRC, and particularly in males. This study aims to characterize ferroptosis-related molecular patterns across sex and KRAS status, their associations with prognosis, and exploratory molecular–drug response associations. We integrated CRC transcriptomics and metabolomics datasets to dissect sex- and KRAS-specific ferroptosis features. Permutation-based variable importance analysis (VIMP) and Gaussian mixture modeling (GMM) were used to assess KRAS-associated molecular patterns. Gene regulatory network (GRN) analysis examined pathway-level regulation, and random survival forest with backward elimination (RSF-BE) ​to prioritize prognostic features. Drug sensitivity was examined using CRC cell line data in which we linked gene expression to therapeutic responses. KRAS-mutant tumors from male patients have distinct ferroptosis gene expression including upregulated SLC7A11 (a ferroptosis suppressor) and downregulated SLC1A5 (a driver). GRN analysis showed that oxidative phosphorylation and glutathione metabolism pathways are differentially regulated in KRAS-mutant tumors from males. Survival analysis revealed that arginine synthesis and glutathione-related genes and metabolites, are ​associated with prognosis for males with​ KRAS-mutant CRC​. Finally, expression of ferroptosis-inhibiting genes ( DHODH , GCH1 , AIFM2 ) was associated with resistance to selected anticancer drugs in male-derived KRAS-mutant CRC cell lines. These findings suggest that ferroptosis-related redox dependencies differ by sex in KRAS-mutant CRC; functional and prospective studies are required before any clinical or therapeutic inference can be drawn.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2026-11-20
DOI
https://doi.org/10.1186/s12885-026-17299-y
Primary Topic
Ferroptosis and cancer prognosis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Sex- and KRAS mutation-associated ferroptosis and redox signatures in colorectal cancer: an integrative multi-cohort analysis

Caroline Helen Johnson, Yisha Yao, Sajid Ali Khan, Shuangge Ma et al.
2 links
BMC Cancer
Ferroptosis and cancer prognosis
article

Sex- and KRAS mutation-associated ferroptosis and redox signatures in colorectal cancer: an integrative multi-cohort analysis

Caroline Helen Johnson, Yisha Yao, Sajid Ali Khan, Shuangge Ma, Xinyi Shen, John Quackenbush, Chen Chen, Hong Yan
article en

Abstract

KRAS mutations are associated with poorer prognosis in males with colorectal cancer (CRC) compared with females and KRAS wild-type (WT) tumors, yet the sex-specific mechanisms remain unclear. Emerging studies suggest that ferroptosis is suppressed in KRAS-mutant CRC, and particularly in males. This study aims to characterize ferroptosis-related molecular patterns across sex and KRAS status, their associations with prognosis, and exploratory molecular–drug response associations. We integrated CRC transcriptomics and metabolomics datasets to dissect sex- and KRAS-specific ferroptosis features. Permutation-based variable importance analysis (VIMP) and Gaussian mixture modeling (GMM) were used to assess KRAS-associated molecular patterns. Gene regulatory network (GRN) analysis examined pathway-level regulation, and random survival forest with backward elimination (RSF-BE) ​to prioritize prognostic features. Drug sensitivity was examined using CRC cell line data in which we linked gene expression to therapeutic responses. KRAS-mutant tumors from male patients have distinct ferroptosis gene expression including upregulated SLC7A11 (a ferroptosis suppressor) and downregulated SLC1A5 (a driver). GRN analysis showed that oxidative phosphorylation and glutathione metabolism pathways are differentially regulated in KRAS-mutant tumors from males. Survival analysis revealed that arginine synthesis and glutathione-related genes and metabolites, are ​associated with prognosis for males with​ KRAS-mutant CRC​. Finally, expression of ferroptosis-inhibiting genes ( DHODH , GCH1 , AIFM2 ) was associated with resistance to selected anticancer drugs in male-derived KRAS-mutant CRC cell lines. These findings suggest that ferroptosis-related redox dependencies differ by sex in KRAS-mutant CRC; functional and prospective studies are required before any clinical or therapeutic inference can be drawn.

BMC Cancer
Harvard University (US), Yale University (US), Columbia University (US)
Good health and well-being
Ferroptosis and cancer prognosis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon